Dendreon Reports Third Quarter 2007 Financi... (lication (BLA) and support the eff...)

HOME >> BIOLOGY >> TECHNOLOGY

Dendreon Reports Third Quarter 2007 Financial Results

Date:11/15/2007

lication (BLA) and support the

efficacy claim for PROVENGE.

-- Implemented a committed equity financing facility under which the

Company may sell up to $130 million of its registered common stock to

Azimuth Opportunity, Ltd. over an 18-month period. Dendreon is not

obligated to utilize any of the $130 million facility and remains free

to enter into and consummate other equity and debt financing

transactions.

-- Results from a Phase 1 study of NEUVENGE, an investigational active

cellular immunotherapy, were published in the August 20th issue of the

Journal of Clinical Oncology. The article highlighted the safety

profile, immune response and clinical activity of NEUVENGE in women

with HER2/neu-positive breast cancer who have failed standard therapy.

"We achieved an important milestone this quarter by completing enrollment of our Phase 3 IMPACT trial of PROVENGE, a therapy we believe has the potential to positively impact the lives of many prostate cancer patients who currently have few treatment options," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are grateful to the patients, clinical investigators and nurses who participated in this study. In addition, we would like to thank our vendors and suppliers, in particular the American Red Cross, Progenitor Cell Therapy and the Mayo Clinic, each of which provided high-quality, consistently excellent cell processing and service throughout the trial. We look forward to receiving interim results from this important study next year."

Conference Call Information

Dendreon will host a conference call today at 1:30 p.m. PT, 4:30 p.m. ET. To access the live call, dial 1-877-397-0235 (domestic) or +1 719-325-4876 (international). The call will also be audio webcast and will be available from the Company's website at http://www
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007

Post Your Comments:

Dendreon Reports Third Quarter 2007 Financi...(lication (BLA) and support the eff...)